Jason B Liu1,2, Jinman Cai3, Mashaal Dhir4, Alessandro Paniccia2, Amer H Zureikat2, Kimberly M Ramonell1, Kelly L McCoy1, Sally E Carty1, Linwah Yip5. 1. Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 2. Division of Gastrointestinal Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 4. Division of Hepatobiliary Surgery and Surgical Oncology, Department of Surgery, Upstate University Hospital, Syracuse, NY, USA. 5. Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. yipl@upmc.edu.
Abstract
BACKGROUND: Liver metastasis from duodenopancreatic neuroendocrine neoplasms (DP-NENs) is a major cause of mortality in multiple endocrine neoplasia type 1 (MEN1) patients, yet much of their natural history is unknown. METHODS: This longitudinal, retrospective cohort study analyzed all MEN1 patients with imageable functional (F) and nonfunctional (NF) DP-NENs (1990-2021) for liver metastasis-free survival (LMFS) and overall survival (OS). RESULTS: Of 138 patients, 85 (61.6%) had imageable DP-NENs (28 F, 57 NF), and the mean largest tumor size was 1.8 ± 1.4 cm. Multifocality was present in 32 patients (37.7%). Surgery was performed for 49 patients (57.7%). During an 11-year median follow-up period (IQR, 6-17 years), 23 (27.1%) of the patients had liver metastasis, and 19 (22.4%) patients died. Death was attributed to liver metastasis in 60% of cases. The patients with F-DP-NENs versus NF-DP-NENs more often had liver metastasis (46.4% vs. 15.8%; p = 0.002) but had similar 10-year LMFS (80.9 vs. 87.0%; p = 0.44) and OS (82.7 vs. 94.3%; p = 0.69). The patients with NF-DP-NENs had surgery when their tumors were larger (p < 0.001). Tumor size was not associated with liver metastasis (p = 0.89). The average growth rate was 0.04 cm/year (SE, 0.02 cm/year; p = 0.01) during active surveillance for NF-DP-NENs (n = 38). Liver metastasis developed in four patients with tumors smaller than 2 cm. The risk of liver metastasis was independent of surgery (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.21-2.93; p = 0.72) and death (HR, 0.51; 95% CI, 0.08-3.06; p = 0.46). CONCLUSIONS: Although the observed outcomes in this study were better than historical data, small NF-DP-NENs still developed liver metastasis and liver metastasis remains a major cause of death. These results suggest that size as a sole criterion for surgery may be insufficient to predict tumor behavior.
BACKGROUND: Liver metastasis from duodenopancreatic neuroendocrine neoplasms (DP-NENs) is a major cause of mortality in multiple endocrine neoplasia type 1 (MEN1) patients, yet much of their natural history is unknown. METHODS: This longitudinal, retrospective cohort study analyzed all MEN1 patients with imageable functional (F) and nonfunctional (NF) DP-NENs (1990-2021) for liver metastasis-free survival (LMFS) and overall survival (OS). RESULTS: Of 138 patients, 85 (61.6%) had imageable DP-NENs (28 F, 57 NF), and the mean largest tumor size was 1.8 ± 1.4 cm. Multifocality was present in 32 patients (37.7%). Surgery was performed for 49 patients (57.7%). During an 11-year median follow-up period (IQR, 6-17 years), 23 (27.1%) of the patients had liver metastasis, and 19 (22.4%) patients died. Death was attributed to liver metastasis in 60% of cases. The patients with F-DP-NENs versus NF-DP-NENs more often had liver metastasis (46.4% vs. 15.8%; p = 0.002) but had similar 10-year LMFS (80.9 vs. 87.0%; p = 0.44) and OS (82.7 vs. 94.3%; p = 0.69). The patients with NF-DP-NENs had surgery when their tumors were larger (p < 0.001). Tumor size was not associated with liver metastasis (p = 0.89). The average growth rate was 0.04 cm/year (SE, 0.02 cm/year; p = 0.01) during active surveillance for NF-DP-NENs (n = 38). Liver metastasis developed in four patients with tumors smaller than 2 cm. The risk of liver metastasis was independent of surgery (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.21-2.93; p = 0.72) and death (HR, 0.51; 95% CI, 0.08-3.06; p = 0.46). CONCLUSIONS: Although the observed outcomes in this study were better than historical data, small NF-DP-NENs still developed liver metastasis and liver metastasis remains a major cause of death. These results suggest that size as a sole criterion for surgery may be insufficient to predict tumor behavior.
Authors: Rachel S van Leeuwaarde; Carolina R C Pieterman; Anne M May; Olaf M Dekkers; Anouk N van der Horst-Schrivers; Ad R Hermus; Wouter W de Herder; Madeleine L Drent; Peter H Bisschop; Bas Havekes; Menno R Vriens; Gerlof D Valk Journal: Neuroendocrinology Date: 2020-05-04 Impact factor: 4.914
Authors: Rachel S van Leeuwaarde; Carolina R C Pieterman; Eveline M A Bleiker; Olaf M Dekkers; Anouk N van der Horst-Schrivers; Ad R Hermus; Wouter W de Herder; Madeleine L Drent; Peter H Bisschop; Bas Havekes; Menno R Vriens; Gerlof D Valk Journal: J Clin Endocrinol Metab Date: 2018-06-01 Impact factor: 5.958
Authors: Frederic Triponez; Samira M Sadowski; François Pattou; Catherine Cardot-Bauters; Eric Mirallié; Maëlle Le Bras; Frédéric Sebag; Patricia Niccoli; Sophie Deguelte; Guillaume Cadiot; Gilles Poncet; Jean-Christophe Lifante; Françoise Borson-Chazot; Philippe Chaffanjon; Olivier Chabre; Fabrice Menegaux; Eric Baudin; Philippe Ruszniewski; Hélène Du Boullay; Pierre Goudet Journal: Ann Surg Date: 2018-07 Impact factor: 12.969
Authors: Bruno Niederle; Andreas Selberherr; Detlef K Bartsch; Maria L Brandi; Gerard M Doherty; Massimo Falconi; Pierre Goudet; Thorvardur R Halfdanarson; Tetsuhide Ito; Robert T Jensen; Alberto Larghi; Lingaku Lee; Kjell Öberg; Marianne Pavel; Aurel Perren; Samira M Sadowski; Francesco Tonelli; Frédéric Triponez; Gerlof D Valk; Dermot O'Toole; David Scott-Coombes; Rajesh V Thakker; Geoffrey B Thompson; Giorgio Treglia; Bertram Wiedenmann Journal: Neuroendocrinology Date: 2020-09-24 Impact factor: 4.914